An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19

NCT04434248 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

330

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Favipiravir
DRUG: Standard of Care

Sponsor

Chromis LLC

Collaborators

[object Object]